GlassScriptPhysician profile
Glenn K Moran
NPI 1801850672
$10,030.49
in general payments reported to CMS, 2019-2025
29 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,327 · 2020: $947 · 2021: $1,114 · 2022: $1,152 · 2023: $1,408 · 2024: $1,428 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,386 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,385.50 |
| Education | $104.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,011.83 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,701.41 | 2019-2025 | |
| Abbvie INC. | $1,391.30 | 2019-2025 | |
| Novo Nordisk INC | $846.21 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $586.50 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $550.55 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $415.31 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $407.10 | 2019-2023 | Livalo, Seglentis |
| Antares Pharma, INC. | $299.95 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $296.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $292.72 | 2020-2024 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $230.17 | 2024-2025 | Contrave |
| Amgen INC. | $182.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $153.09 | 2019-2021 | |
| Astellas Pharma US INC | $116.23 | 2023 | Myrbetriq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $89.53 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $63.61 | 2022-2023 | |
| Esperion Therapeutics, INC. | $62.36 | 2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $49.60 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.74 | 2022 | |
| Allergan, INC. | $45.98 | 2019-2020 | |
| Gilead Sciences, INC. | $45.74 | 2020-2022 | |
| Halozyme INC | $29.33 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.54 | 2023 | |
| Sanofi Pasteur INC. | $22.22 | 2023 | |
| Shield Therapeutics INC | $18.79 | 2024 | |
| Genentech USA, INC. | $18.63 | 2019 | |
| Acella Pharmaceuticals, LLC | $17.44 | 2024 | NP Thyroid 60 |
| Lucid Diagnostics INC. | $15.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.